CORE A: Administrative Core

总结/摘要 行政核心 行政核心（AC）是带头的神经退行性疾病和转化中心的成功 神经科学（CNTN）。该CNTN是一个多学科，主题凝聚力，面向任务，翻译 在南内华达州（NV），神经科学研究计划专注于神经退行性疾病（NDD）。的 该中心是位于拉斯维加斯的克利夫兰诊所卢鲁沃脑健康中心（LRCBH） 拉斯维加斯，内华达州（NV）和内华达州拉斯维加斯大学（UNLV）。我们的研究中心对于 内华达州南部的人口演变这一点可以从国家官员强烈支持我们的 定期与AC领导层互动，询问进度和支持需求。 在CNTN第一阶段，AC完成的工作已经改变了转化神经科学 在南NV的研究环境。AC的显著成就是：1-投资于尖端技术 神经科学和NDD研究的基础设施; 2- 6名初级研究员（JIs）的指导， 毕业于独立的职位; 3-创建临床和转化研究核心（CTRC）， 建立和深入表型一个新的纵向队列的患者患有NDD;和4-建立一个 数据管理和统计核心，用于安全地存储和管理大型生物医学数据集，并协助CNTN 研究人员进行统计分析。AC使用了由以下开发的创新方法编制的数据： 评估小组负责监督CNTN核心和项目的运作。 对于第二阶段，咨询委员会打算利用评估股的数据进行决策。数据将 审查如何优化研究基础设施的发展，以支持新的 项目，CNTN调查员的职业发展，以及COBRE支持期后的可持续性。 我们战略的第一步是增加AC领导层，增加两名共同主任（Sabbagh博士和 Kinney）和一名助理主任（Cummings博士），以有效管理CNTN的快速增长 企业.我们新的AC领导层雄心勃勃，要在第二阶段实现五个具体目标。首先，AC将 加强CNTN核心、项目和咨询委员会的协调。第二，AC将推进 通过增加我们的队列规模和加强基础研究项目，包括 初级和试点项目调查员的项目。第三，AC将促进所有人的职业发展 CNTN人员。第四，咨询委员会将促进对全国土著人网络活动的强有力的评估进程， 数据用于决策。第五，AC将利用COBRE、机构、行业和慈善机构的支持， 强调南内华达州神经科学研究的可持续未来。因此，AC领导人完全 致力于在南内华达州发展转化神经科学研究生态系统，并协助国家 官员们正在寻找有效的应对措施，以遏制内华达州即将到来的NDD大流行。

SUMMARY/ABSTRACT Administrative Core The Administrative Core (AC) is spearheading the success of the Center for Neurodegeneration and Translational Neuroscience (CNTN). The CNTN is a multidisciplinary, thematically cohesive, mission-oriented, translational neuroscience research program focused on neurodegenerative diseases (NDD) in Southern Nevada (NV). The Center is a dynamic collaboration between the Cleveland Clinic Lou Ruvo Center for Brain Health (LRCBH) in Las Vegas, Nevada (NV), and the University of Nevada Las Vegas (UNLV). Our research center is very significant for the demographic evolution of Southern NV. This is evidenced by the fact that State Officials strongly support our project and interact regularly with AC leadership to inquire about progress and need for support. During CNTN Phase 1, the work accomplished by AC has transformed the translational neuroscience research environment in Southern NV. The significant achievements of AC are: 1- the investment in cutting-edge infrastructure for neuroscience and NDD research; 2- the mentoring of six Junior Investigators (JIs) who graduated with independent positions; 3- the creation of a Clinical and Translational Research Core (CTRC) to build and deeply phenotype a new longitudinal cohort of patients suffering NDD; and 4- the establishment of a Data Management and Statistics Core to securely store and manage large biomedical datasets and assist CNTN investigators with statistical analyses. AC has utilized the data compiled from innovative methods developed by the Assessment Unit to monitor the operations of CNTN Cores and projects. For Phase 2, the AC intends to exploit the data from the Assessment Unit for decision-making. The data will be scrutinized to strategize on how to optimize the development of research infrastructure that will support new projects, the career development of CNTN investigators, and sustainability beyond the COBRE support period. The first step in our strategy is the augmentation of the AC leadership with two co-Directors (Drs. Sabbagh and Kinney) and one Assistant Director (Dr. Cummings) to efficiently manage the rapid growth of the CNTN enterprise. Our new AC leadership ambitions to accomplish five specific aims during Phase 2. First, AC will enhance the coordination of CNTN Cores, projects, and advisory Committees. Second, the AC will advance scientific research by increasing the size of our cohort and fortifying fundamental research projects, including the projects by junior and pilot project investigators. Third, the AC will enhance the career development of all CNTN personnel. Fourth, the AC will foster a robust assessment process of CNTN activities to further use the data for decision-making. Fifth, AC will utilize COBRE, institutional, industry, and philanthropic support to accentuate the sustainable future of neuroscience research in Southern NV. Therefore, AC leaders are fully committed to develop the translational neuroscience research ecosystem in Southern NV and assist State Officials with finding an impactful response to curb the upcoming NDD pandemic in NV.